Source: Annual Congress 2013 –Significance of intestinal and respiratory tract cross-talk in chronic lung diseases
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
S. Zielen (Francfort, Germany). Probiotics: promise or failure to influence airway disease. Annual Congress 2013 –Significance of intestinal and respiratory tract cross-talk in chronic lung diseases

Member's Comments

No comment yet.

Related content which might interest you: Presentation by an expert: Emerging relationships between airway microbiota and chronic respiratory disease : mechanisms of disease onset Source: Lung Science Conference 2013 - Early origins and mechanisms of chronic lung disease Year: 2013 The lung microbiome in obstructive airways disease: potential pathogenetic roles Source: Eur Respir Monogr 2019; 83: 140-157 Year: 2019 Dismantling airway disease with the use of new pulmonary function indices Source: Eur Respir Rev, 28 (151) 180122; 10.1183/16000617.0122-2018 Year: 2019 Targeting airway inflammation in asthma: current and future therapies Source: Annual Congress 2009 - MP7 - Targeting airway inflammation in asthma: current and future therapies Year: 2009 Targeting airway inflammation in asthma: current and future therapies Source: Annual Congress 2009 - PG13 Asthma: pathology and treatment Year: 2009 The effect of statin therapy in patients with chronic obstructive airway disease Source: International Congress 2015 – COPD: notable points Year: 2015 Nonpharmacological and pharmacological interventions to prevent or reduce airway remodelling Source: Eur Respir J 2007; 30: 574-588 Year: 2007 Chronic obstructive pulmonary disease in heart failure: prevalence, therapeutic and prognostic implications Source: Annual Congress 2009 - Biomarkers, comorbidities and prognosis of COPD Year: 2009 What are the common biological mechanisms that lead to obstructive airway disease? Source: International Congress 2016 – Early life origins of asthma and COPD Year: 2016 Host–microbe interactions in distal airways: relevance to chronic airway diseases Source: Eur Respir Rev 2015; 24: 78-91 Year: 2015 Beyond corticosteroids: future prospects in the management of inflammation in COPD Source: Eur Respir Rev 2011; 20: 175-182 Year: 2011 Macrolides, inflammation and the lung microbiome: cause or effect? Source: International Congress 2018 – State of the art session: Airways disease Year: 2018 Clinical relevance of airway remodelling in airway diseases Source: Eur Respir J 2007; 30: 134-155 Year: 2007 Z-alpha1-antitrypsin polymers and small airways disease: a new paradigm in COPD development? Source: Virtual Congress 2020 – Prediction of outcomes in obstructive diseases Year: 2020 Presentation by an expert: Early influences of the airway microbiome on obstructive lung disease Source: Lung Science Conference 2013 - Early origins and mechanisms of chronic lung disease Year: 2013 Improving adherence in chronic airways disease: are we doing it wrongly? Source: Breathe, 17 (2) 210022; 10.1183/20734735.0022-2021 Year: 2021 COPD as a lung disease with heterogeneous systemic inflammatory consequences: clinical impact Source: Research Seminar 2011 - Physical activity, nutritional status and systemic inflammation in COPD Year: 2011 The role of cluster analysis in defining phenotypes of obstructive airway diseases: is there a need for a new taxonomy of obstructive airway diseases? Source: Annual Congress 2011 - PG11 Update of phenotypes of asthma and COPD Year: 2011 Neutrophils in chronic inflammatory airway diseases: can we target them and how? Source: Eur Respir J 2010; 35: 467-469 Year: 2010